News

ABDİ İBRAHİM'S GMP CERTIFICATE IN KAZAKHSTAN PRODUCTION PLANT
Abdi İbrahim Chairman of the Board of Directors Nezih Barut:

 2020 VISION TARGETS TO BE ONE OF THE MOST FIRST  100 FORST DRUGS ON THE WORLD


Shortly after Abdi İbrahim, the leader of the Turkish pharmaceutical industry, the production facility in Abdi İbrahim Global Pharm in Kazakhstan passed the operation, he was entitled to receive GMP which is one of the most important documents given in the field of good production practices. Abdi İbrahim Chairman of the Board of Directors Nezih Barut, about the facility "2020 vision of reaching $ 1 billion in sales, the world's largest 100 drug companies have the goal to be one. In this direction, we are expanding our overseas investments both geographically and carrying out studies that will bring our production capability to the highest level. We are experiencing the excitement of our new investment in Kazakhstan as well as in Algeria. We are proud to have GMP certification shortly after production of our facilities established in Kazakhstan with an investment of $ 60 million."
Abdi İbrahim, who has been continuing his activities for the last 105 years to improve his life and future with his pioneering, brave and innovative works, is approaching his 2020 goals step by step with Kazakhstan investment which is the most important ring of investments abroad. Abdi İbrahim, who has been the unchallenged market leader since 2003 in Turkey, is determined to remain permanently in foreign markets with the investment incidents he has made in recent years.
Abdi İbrahim's investment in Esenyurt for the campus in which the production facility, R & D and logistics centers are located is 285 million dollars. Following this investment, Abdi İbrahim's $ 60 million investment in Kazakhstan, which has laid the foundations of Turkey's largest biotechnology drug production facility with an investment budget of US $ 100 million last year, has begun to produce 24 million boxes per year.

The plant in Kazakhstan, where Abdi Ibrahim laid the foundation in 2013, shortly after production, was entitled to receive the GMP Certificate as the reference document given in the field of best production practices. Abdi İbrahim Global Pharm, which is based on a total area of 12 thousand square meters and 190 people working, will produce about 100 products, mainly diabetes and antiviral products, products used in the treatment of central nervous system diseases and cardiovascular products.

It is foreseen that Abdi İbrahim Global Pharm, Abdi İbrahim's most modern, most comprehensive facility, which is the first country of Abdi İbrahim's overseas operations, will be contributed 15 million dollars to Abdi İbrahim's total crop in 2016.

 

SITE MAP
INFORMATION SOCIETY SERVICES
© 2011-2017 Abdi İbrahim İlaç Sanayi ve Tic A.Ş.
The information provided on this site is not intended as an advice. Information provided should be discussed with your healthcare professional.
Phone: 0212 366 8400
E-Mail: info@abdiibrahim.com.tr